The overall purpose was to activate ARG1-specific T cells to target the tumor microenvironment, strengthen or induce local Th1 inflammation, and potentially eliminate or reprogram ARG1-expressing immune suppressive cells. The gene discussed is ARG1; the disease is neoplasm.